Vaccines Today—July 10 2026

LucidQuest

4 hours ago

This week’s Vaccine Research update highlights regulatory momentum, clinical progress, platform partnerships, and early-stage vaccine innovation.

In Today’s Newsletter

Dive deeper

🤖 SK bioscience leads Gates-backed ROTOR vaccine AI project [1] [Global • 06 Jul 2026]

https://biopharmaapac.com/news/45/8139/sk-bioscience-to-lead-gates-foundation-backed-ai-platform-for-vaccine-clinical-development.html
Context: ROTOR brings SK bioscience, PATH, Slalom, and SK AX into a Gates Foundation-funded AI platform project.
Key point: The platform will support evidence synthesis and clinical development decisions for injectable rotavirus vaccines.
Implication: Signals pipeline investment and modality expansion.

🧬 LJI, Scripps, and IAVI report pre-clinical HIV vaccine antibody response [2] [US • 06 Jul 2026]

https://www.lji.org/news-events/news/post/new-hiv-vaccine-shows-unprecedented-success-in-preclinical-study/
Context: The vaccine approach was tested in rhesus macaques and used germline targeting to guide B cell maturation.
Key point: Researchers reported broadly neutralizing HIV antibodies in about 44% of animals; infection prevention was not tested.
Implication: Signals pipeline investment and modality expansion.

💉 Moderna mRNA flu vaccine gains FDA advisory committee support [3] [US • 06 Jul 2026]

https://www.ajmc.com/view/fda-advisory-committee-supports-moderna-mrna-flu-vaccine-review
Context: FDA’s advisory committee voted 9-0 that benefits outweighed risks for mRNA-1010, branded mFlusiva, in adults 50-plus.
Key point: The review includes Phase 3 data, with a PDUFA goal date of 05 Aug 2026.
Implication: Introduces competition that may affect pricing and formulary access.

💊 Vaxart oral COVID-19 vaccine reports 12-month safety data [4] [US • 06 Jul 2026]

https://investors.vaxart.com/news-releases/news-release-details/vaxart-reports-topline-12-month-safety-data-400-participant
Context: The Phase 2b sentinel cohort included about 400 participants, comparing oral pill vaccine with an approved mRNA comparator.
Key point: No vaccine-related serious adverse events or sustained Grade 3 or higher vaccine-related adverse events were reported.
Implication: May influence prescriber choice and payer reviews pending full data.

🌲 Immunomic Therapeutics starts Phase 1 saRNA allergy vaccine trial [5] [Japan • 07 Jul 2026]

https://biopharmaapac.com/news/31/8143/immunomic-therapeutics-doses-first-patient-in-phase-1-trial-of-sarna-allergy-vaccine-in-japan.html
Context: ITI-9001 uses the UNITE self-amplifying RNA platform and targets Japanese cedar pollen allergy.
Key point: The first participant was dosed less than one month after PMDA clearance; no significant safety concerns were observed to date.
Implication: Signals pipeline investment and modality expansion.

🧫 Boehringer licenses PVT viral-vector platform for cancer vaccines [6] [Germany/Austria • 07 Jul 2026]

https://www.fiercebiotech.com/biotech/boehringer-bags-pvts-viral-vector-platform-cancer-vaccine-rd
Context: Boehringer Ingelheim secured an exclusive license to Prime Vector Technologies’ Orf virus platform for cancer vaccines.
Key point: The deal covers cancer vaccine R&D, while PVT retains rights for infectious disease and other uses.
Implication: Signals pipeline investment and modality expansion.

🦟 Indonesia–China mRNA dengue vaccine prototype advances [7] [Indonesia–China • 08 Jul 2026]

https://en.antaranews.com/amp/news/421955/indonesia-china-mrna-dengue-vaccine-to-boost-global-health-bpom
Context: University of Indonesia and Tsinghua University are developing an mRNA dengue vaccine prototype with BPOM support.
Key point: The program is in pre-clinical testing; BPOM said the vaccine is not yet ready for use.
Implication: Signals pipeline investment and modality expansion.

Why it matters

Vaccine R&D is widening across AI decision-support, RNA, oral delivery, viral vectors, and germline-targeted immunology. [1][2][4][5][6][7]
Regulatory momentum for Moderna’s mFlusiva could make mRNA a near-term factor in seasonal flu prevention. [3]
Several programs remain early or incomplete, so interpretation depends on full clinical datasets and regulatory review. [2][4][5][7]
Global access themes recur across rotavirus, dengue, COVID-19, and allergy vaccine work. [1][4][5][7]

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🧰 See our full range of services. Discover how we can help you.

🎯 Catch up on the Top Vaccine news from the past two weeks, curated by the LucidQuest team.

🎬 Watch on YouTube.

FAQ

What is SK bioscience’s ROTOR project?

ROTOR is a Gates Foundation-funded AI decision-support platform for vaccine clinical development, initially focused on injectable rotavirus vaccines. It includes SK bioscience, PATH, Slalom, and SK AX. [1]

Did the LJI, Scripps, and IAVI HIV vaccine prevent infection?

No prevention test was reported in the supplied source. The key pre-clinical result was induction of broadly neutralizing HIV antibodies in non-human primates. [2]

What is Moderna mFlusiva?

mFlusiva is Moderna’s mRNA-1010 seasonal influenza vaccine candidate for adults 50 and older. An FDA advisory committee supported its review, with a PDUFA date of 05 Aug 2026. [3]

What did Vaxart report for its oral COVID-19 vaccine?

Vaxart reported 12-month topline safety data from a 400-participant Phase 2b sentinel cohort. The cohort was not powered for comparative efficacy. [4]

What is Immunomic Therapeutics’ ITI-9001?

ITI-9001 is an investigational self-amplifying RNA allergy vaccine using Immunomic’s UNITE platform. It targets CryJ2 in Japanese cedar pollen allergy. [5]

What is BPOM’s role in the Indonesia–China dengue vaccine project?

BPOM said it would support oversight for safety, efficacy, and quality as the University of Indonesia and Tsinghua University advance the mRNA dengue vaccine prototype. [7]

Entities / Keywords

SK bioscience, ROTOR, Research Optimization & Trial Outcome Recommender, Gates Foundation, PATH, Slalom, SK AX, injectable rotavirus vaccine, LMICs.
La Jolla Institute for Immunology, LJI, Scripps Research, IAVI, CHAVD, HIV vaccine, broadly neutralizing antibodies, germline targeting, rhesus macaques, HVTN 144, IAVI G004.
Moderna, mRNA-1010, mFlusiva, FDA, VRBPAC, PDUFA, seasonal influenza vaccine, adults 50-plus.
Vaxart, oral pill COVID-19 vaccine, Phase 2b, sentinel safety cohort, XBB, KP.2, Project NextGen, BARDA, NIAID.
Immunomic Therapeutics, ITI, ITI-9001, UNITE, self-amplifying RNA, saRNA, Japanese cedar pollen allergy, CryJ2, PMDA.
Boehringer Ingelheim, Prime Vector Technologies, PVT, Orf virus, ORFV, cancer vaccine, viral vector, ViraTherapeutics, VSV-GP, BI 1831169.
University of Indonesia, Tsinghua University, BPOM, mRNA dengue vaccine, dengue serotypes 1–4, LPDP, PT Etana.